Connect with us

Hi, what are you looking for?

Deluxe Investment GroupDeluxe Investment Group

Investing

Dr. Marty Makary advances out of key committee in bid for FDA confirmation

President Donald Trump’s nominee to lead the Food and Drug Administration (FDA), Dr. Marty Makary, passed a key committee vote 14-9 on Thursday morning, clearing the way for a full Senate vote on his nomination. 

If confirmed before the full Senate, Makary will work alongside the nominee for National Institute of Health (NIH) Director Dr. Jay Bhattacharya to achieve Secretary of Health and Human Services Robert F. Kennedy Jr.’s Make America Healthy Again agenda. 

The Senate Committee on Health, Education, Labor and Pensions(HELP) voted in favor of Makary’s confirmation following his committee hearing one week ago today. 

‘We now have a generational opportunity in American healthcare. President Trump and Secretary Kennedy’s focus on healthy foods has galvanized a grassroots movement in America. Childhood obesity is not a willpower problem, and the rise of early-onset Alzheimer’s is not a genetic cause. We should be, and we will, be addressing food as it impacts our health,’ Makary said last week. 

‘Thanks to the courage of President Trump and Secretary Kennedy, we now have a generational opportunity to usher in radical transparency to facilitate more cures, meaningful treatments and diagnostics at the FDA to help people take care of their own health,’ Makary added.

Makary was grilled by Democrats last week on vaccines, abortion, chronic illness and food safety. When repeatedly asked by Democratic senators on the committee whether he would revoke the approval process for Mifepristone, Makary said any decision on the abortion pill will come down to science. 

‘I have no preconceived plans on Mifepristone policy except to take a solid, hard look at the data and to meet with the professional career scientists who have reviewed the data at the FDA, and to build an expert coalition to review the ongoing data,’ he said. 

Makary, who advocated for natural immunity during the COVID-19 pandemic, flipped a question about vaccine processes around on Sen. Patty Murray, D-Wash., during his confirmation hearing, telling her to ask former President Joe Biden why he skipped a key step when it came to the COVID-19 booster. 

‘So, if you are confirmed, will you commit to immediately reschedule that FDA Vaccine Advisory Committee meeting to get the expert views?’ Sen. Patty Murray, D-Wash., asked Trump’s FDA pick. 

‘I would re-evaluate which topics deserve a convening of the advisory committee members on [Vaccines and Related Biological Products Advisory Committee] and which may not require a convening,’ Makary replied, adding that he was not a part of the decision. 

Trump FDA nominee turns vaccine question on Dem, recalling controversial Biden decision

When asked again by Murray, he said: ‘Well, you can ask the Biden administration that chose not to convene the committee meeting for the COVID vaccine booster.’

He vowed during his committee hearing to lead his own Department of Government Efficiency (DOGE) investigations if confirmed. DOGE has terminated the employment of thousands of probationary HHS employees, including those at the FDA, since Trump took office. 

‘If confirmed, I will do my own independent assessment on personnel. I welcome input on efficiencies at the agency. At the same time, I want to make sure that the scientists and food inspectors and staff, central to the core mission of the agency, have all the resources they need to do their job well,’ Makary said last week. 

Makary has long been a critic of the FDA. He penned an opinion piece in 2021 that called for ‘fresh leadership at the FDA to change the culture at the agency and promote scientific advancement, not hinder it.’

Trump nominated Johns Hopkins School of Medicine professor, pancreatic surgeon and former Fox News medical contributor Dr. Marty Makary for FDA commissioner in November. 

‘I am very pleased to nominate Marty Makary MD, MPH, FACS, for FDA Commissioner,’ Trump said in a statement. ‘FDA has lost the trust of Americans, and has lost sight of its primary goal as a regulator. The Agency needs Dr. Marty Makary, a Highly Respected Johns Hopkins Surgical Oncologist and Health Policy Expert, to course-correct and refocus the Agency.’ 

Trump said that Makary will ‘work under the leadership of Robert F. Kennedy Jr. to, among other things, properly evaluate harmful chemicals poisoning our Nation’s food supply and drugs and biologics being given to our Nation’s youth, so that we can finally address the Childhood Chronic Disease Epidemic.’

Fox News Digital’s Julia Johnson contributed to this report.

This post appeared first on FOX NEWS

Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!



    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    You May Also Like

    Latest News

    Sister Stephanie Schmidt had a hunch about what her fellow nuns would discuss over dinner at their Erie, Pennsylvania, monastery on Wednesday night. The...

    Latest News

    In the final three weeks of the presidential race, former president Donald Trump and his advisers have attacked one particular foe more than three...

    Latest News

    “And there’s very few states that benefit like you do from fracking. I mean, you have 500,000 jobs.” — Former president Donald Trump, remarks...

    Latest News

    A former deputy Palm Beach County sheriff who fled to Moscow and became one of the Kremlin’s most prolific propagandists is working directly with...

    Disclaimer: Deluxeinvestmentgroup.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 deluxeinvestmentgroup.com